Sugi Predict

Sugi Predict / Compounds / SCHEMBL1967124

SCHEMBL1967124

SCHEMBL1967124

COc1ccc(/C=C/[N+](=O)[O-])cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FBP1 P09467 9/20 0.58
▸ VCP P55072 5/20 0.54
▸ TUBB4A P04350 1/20 0.51
▸ TUBB P07437 1/20 0.51
▸ TUBA3C P0DPH7 1/20 0.51
▸ TUBA1B P68363 1/20 0.51
▸ TUBA4A P68366 1/20 0.51
▸ TUBB4B P68371 1/20 0.51
▸ TUBB3 Q13509 1/20 0.51
▸ TUBB2A Q13885 1/20 0.51
▸ TUBB8 Q3ZCM7 1/20 0.51
▸ TUBA3E Q6PEY2 1/20 0.51
▸ TUBA1A Q71U36 1/20 0.51
▸ TUBA1C Q9BQE3 1/20 0.51
▸ TUBB6 Q9BUF5 1/20 0.51
▸ TUBB2B Q9BVA1 1/20 0.51
▸ TUBB1 Q9H4B7 1/20 0.51
▸ EGFR P00533 3/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ LMNA P02545 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1967126 1.00 FBP1 (0.58) FBP1VCPTUBB4ATUBBTUBA3C
SCHEMBL29434397 1.00 FBP1 (0.58) FBP1VCPTUBB4ATUBBTUBA3C
SCHEMBL510103 0.79 TLR4 (0.66) FBP1VCPEGFRALDH1A1LMNA
SCHEMBL510102 0.79 TLR4 (0.66) FBP1VCPEGFRALDH1A1LMNA
SCHEMBL10178295 0.78 FBP1 (0.59) FBP1VCPEGFRALDH1A1LMNA
SCHEMBL21748733 0.78 FBP1 (0.59) FBP1VCPEGFRALDH1A1LMNA
SCHEMBL510978 0.78 MAOA (0.60) FBP1VCPEGFRALDH1A1LMNA
SCHEMBL510979 0.78 MAOA (0.60) FBP1VCPEGFRALDH1A1LMNA
SCHEMBL510488 0.76 MAOA (0.60) FBP1VCPEGFRALDH1A1LMNA
SCHEMBL510487 0.76 MAOA (0.60) FBP1VCPEGFRALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11261155-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICAL CO., LTD. (JP) 2022-03-01 — — US disclosed
US-20210107869-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof KYORIN SEIYAKU KK (JP) 2021-04-15 — — US disclosed
US-20210107869-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof KYORIN SEIYAKU KK (JP) 2021-04-15 — — US disclosed
US-10696630-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2020-06-30 — — US disclosed
US-10696630-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2020-06-30 — — US disclosed
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2019-11-05 — — US disclosed
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof KYORIN PHARMACEUTICALS CO., LTD. (JP) 2019-11-05 — — US disclosed
EP-3305763-B1 DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS KYORIN SEIYAKU KK (JP) 2019-07-24 — — EP disclosed
EP-3305763-B1 DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS KYORIN SEIYAKU KK (JP) 2019-07-24 — — EP disclosed
US-20190161445-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof KYORIN SEIYAKU KK (JP) 2019-05-30 — — US disclosed
EP-3075726-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF Kyorin Pharmaceutical Co., Ltd. (JP) 2016-10-05 — — EP disclosed
WO-2015079692-A1 UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF 杏林製薬株式会社 2015-06-04 — — WO disclosed
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-01 — — US disclosed
EP-2334643-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES Actelion Pharmaceuticals Ltd. (CH) 2011-06-22 — — EP disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 — — US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 — — US disclosed
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF TORAY INDUSTRIES, INC. (JP) 2010-09-16 — — US disclosed
WO-2010044054-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES ACTELION PHARMACEUTICALS LTD (CH) 2010-04-22 — — WO disclosed
EP-2009006-A1 UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES TORAY INDUSTRIES, INC. (JP) 2008-12-31 — — EP disclosed
EP-2009006-A1 UREIDE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES TORAY INDUSTRIES, INC. (JP) 2008-12-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10696630-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 FBP1 898/4885VCP 3288/4885TUBB4A 4491/4885
US-10464891-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 FBP1 898/4885VCP 3288/4885TUBB4A 4491/4885
US-20210107869-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof FPR1, FPR2, FPR3 FBP1 898/4885VCP 3288/4885TUBB4A 4491/4885
US-20190161445-A1 Urea Derivative Or Pharmacologically Acceptable Salt Thereof FPR1, FPR2, FPR3 FBP1 898/4885VCP 3288/4885TUBB4A 4491/4885
US-20110212968-A1 PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES HCRTR2, HCRTR1, HRH3 FBP1 3283/4885VCP 972/4885TUBB4A 1885/4885
US-11261155-B2 Urea derivative or pharmacologically acceptable salt thereof FPR1, FPR2, FPR3 FBP1 898/4885VCP 3288/4885TUBB4A 4491/4885
US-20100234395-A1 UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF UROD, UTS2R, SLC14A1 FBP1 2259/4885VCP 404/4885TUBB4A 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.